TY  - JOUR
AU  - Demnitz-King, Harriet
AU  - Gonneaud, Julie
AU  - Klimecki, Olga M
AU  - Chocat, Anne
AU  - Collette, Fabienne
AU  - Dautricourt, Sophie
AU  - Jessen, Frank
AU  - Krolak-Salmon, Pierre
AU  - Lutz, Antoine
AU  - Morse, Rachel M
AU  - Molinuevo, José Luis
AU  - Poisnel, Géraldine
AU  - Touron, Edelweiss
AU  - Wirth, Miranka
AU  - Walker, Zuzana
AU  - Chételat, Gaël
AU  - Marchant, Natalie L
TI  - Association Between Self-Reflection, Cognition, and Brain Health in Cognitively Unimpaired Older Adults.
JO  - Neurology
VL  - 99
IS  - 13
SN  - 0028-3878
CY  - [S.l.]
PB  - Ovid
M1  - DZNE-2022-01387
SP  - e1422 - e1431
PY  - 2022
AB  - Self-reflection (the active evaluation of ones thoughts, feelings and behaviours) can confer protection against adverse health outcomes. Its impact on markers sensitive to Alzheimer's disease (AD), however, is unknown. The primary objective of this cross-sectional study was to examine the association between self-reflection and AD-sensitive markers.This study utilised baseline data from cognitively unimpaired older adults enrolled in the Age-Well clinical trial and older adults with subjective cognitive decline from the SCD-Well clinical trial. In both cohorts, self-reflection was measured via the reflective pondering subscale of the Rumination Response Scale, global cognition assessed via the Preclinical Alzheimer's Cognitive Composite 5, and a modified late-life Lifestyle-for-Brain-Health (LIBRA) index computed to assess health and lifestyle factors. In Age-Well, glucose metabolism and amyloid deposition were quantified in AD-sensitive grey matter regions via FDG- and AV45-PET scans, respectively. Associations between self-reflection and AD-sensitive markers (global cognition, glucose metabolism, and amyloid deposition) were assessed via unadjusted and adjusted regressions. Further, we explored whether associations were independent of health and lifestyle factors. To control for multiple comparisons in Age-Well, false discovery rate corrected p-values (p FDR) are reported.A total of 134 (mean age 69.3 ± 3.8 years, 61.9
KW  - Aged
KW  - Alzheimer Disease: metabolism
KW  - Amyloid beta-Peptides: metabolism
KW  - Biomarkers: metabolism
KW  - Brain: diagnostic imaging
KW  - Brain: metabolism
KW  - Cognition: physiology
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Cognitive Dysfunction: metabolism
KW  - Cross-Sectional Studies
KW  - Female
KW  - Glucose: metabolism
KW  - Humans
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Positron-Emission Tomography
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Glucose (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:35853750
DO  - DOI:10.1212/WNL.0000000000200951
UR  - https://pub.dzne.de/record/164983
ER  -